Status of Medications Prescribed for Psychiatric Disorders in Korean Pediatric and Adolescent Patients

• Published in: Children (Basel) Vol. 9; no. 1; p. 68
• Main Authors: Jang, In-Woo, Chang, Ji-Eun, Kim, Jongyoon, Rhew, Kiyon
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 05.01.2022; MDPI
• Subjects: Bipolar disorder; Health insurance; Mental disorders; off-label; Pediatrics; Prescription drugs; psychiatric drugs; real-world data; real-world evidence; Teenagers; unlicensed; United States > US; China; real-world data; real-world evidence; unlicensed; psychiatric drugs; pediatrics; off-label
• ISSN: 2227-9067; 2227-9067
• DOI: 10.3390/children9010068

While mental health services for children are increasing, few psychiatric drugs have been approved for such use. We analyzed claim data from 19,557 South Korean pediatric and adolescent patients (<20 years) who were diagnosed with schizophrenia, bipolar disorder, major depressive disorder, anxiety disorder, attention deficit-hyperactivity disorder (ADHD), or a tic disorder. Among these diseases, depressive episodes were the most common, followed by an anxiety disorder, ADHD, bipolar disorder, tic disorder, and schizophrenia. For each disease, prescriptions were categorized as full-label (approved indication with pediatric dosing in the package insert (PI)), partial-label (approved indication without pediatric dosing in the PI), and contraindication (contraindicated for the specific pediatric age in the PI). For schizophrenia, major depressive disorder, and anxiety disorder, more than 50% of the patients were prescribed partial-labeled medications. Additionally, more than 5% of patients with major depressive disorder were prescribed medications that were contraindicated for their age group. Our findings reveal that children with full-labeled psychiatric conditions are commonly administered drugs that are not explicitly approved for either their disease state or age, including off-label and unlicensed drugs. To use pharmaceuticals more safely, expanding drug indications using real-world data are needed.